维普中文期刊产品整合服务
10篇 您的检索式:作者名="Manley AL"
    题名 作者 年代 出处 被引量
1Efficacy, safety, and tolerability of desvenlafaxine 50 mg/day and 100mg/day in outpa- tients with major depressive disorder显示文摘Liebowttz MR Manley AL Padmanabhan SK 2008Curt Med Res Opin2008,24,7:1
2Development andprogression of nephropathy in type 2 diabetes: the UnitedKingdom Prospective Diabetes Study ( UKPDS 64 ) 显示文摘Adler Al Stevens RJ Manley SE 2003Kidney Int2003,63,1:1
3Proactive mitigation of impact of wormholes and sinkholes on routing security in energy-efficient wireless sensor networks显示文摘Huzaifa Al Nahas Jitender S. Deogun Eric D. Manley 2009Wireless Networks2009,,4:1
4Effica- cy, safety, and tolerability of desvenlafaxine 50 mg/day and 100 mg/day in outpatients with major depressive dis- order 显示文摘Liebowitz MR Manley AL Padmanabhan SK et a/ 2008Curr MedRes Opin2008,24,7:1
5Development and progression of nephropathy in type 2 diabetes, the United Kingdom Prospective Diabetes Study ( UKPDS64 ) 显示文摘Adler AI Stevens RJ Manley SE el al 2003Kidney Inl2003,63,1:1
6Development and progression of nephropathy in type 2 diabetes: the United Kingdom Prospective Diabetes Study(UKPDS 64)显示文摘Adler Al Stevens RJ Manley SE 2003Kidney Int2003,63,1:1
7Selective export of MHC class I molecules from the ER after their dissociation from TAP显示文摘Spiliotis ET Manley H Osorio M at al 2000Immunity2000,13,6:1
8Aquaporin - 4 fa-cilitates reabsorption of excess fluid in vasogenic brain edema显示文摘Papadopoulos MC Manley GT Krishna S ei al 2004FasebJ2004,18,:1
9Efficacy, safety, and tolerability of desvenlafaxine 50 mg/day and 100 mg/day in outpatients with major depressive disorder显示文摘LIEBOWITZ MR MANLEY AL PADMANABHAN SK 2008Curr Med Res Opin2008,24,7:1
10Development and progression of nephropathy in type 2 diabetes: the United Kingdom Prospective Diabetes Study(UKPDS 64)显示文摘Adler Al Stevens RJ Manley SE 2003Kidney Int2003,63,1:1
返回顶部 每页显示:
共1页 首页 上一页 第1页 下一页 末页 /1 跳转

网站首页 | 关于我们 | 联系我们 | 产品服务 | 客服中心 | 广告服务 | 版权声明 | 网站联盟 | 友情链接 | 售卡网点

版权所有© 渝B2-20050021-1 渝公网安备 50019002500403号 违法和不良信息举报中心

互联网出版许可证 新出网证(渝)字10号 全国400电话 - 免长途话费